融券方面，博拓生物11月11日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，杭州博拓生物科技股份有限公司位于浙江省杭州市余杭区仓前街道途义路27号，成立日期 2008年11月28日，上市日期2021年9月8日，公司主营业务涉及从事POCT诊断试剂的研发、生产和销 售。主营业务收入构成为：POCT产品业务及其他100.00%。 截至9月30日，博拓生物股东户数7146.00，较上期增加28.00%；人均流通股20897股，较上期减少 21.87%。2025年1月-9月，博拓生物实现营业收入3.08亿元，同比减少20.76%；归母净利润2226.32万 元，同比减少75.04%。 11月11日，博拓生物跌3.55%，成交额5799.96万元。两融数据显示，当日博拓生物获融资买入额 1280.82万元，融资偿还777.66万元，融资净买入503.16万元。截至11月11日，博拓生物融资融券余额合 计3.13亿元。 融资方面，博拓生物当日融资买入1280.82万元。当前融资余额3.13亿元，占流通 ...

Group 1 - The core viewpoint of the news is that Botao Bio has seen a stock price increase of 5.06%, reaching 44.23 CNY per share, with a total market capitalization of 6.605 billion CNY [1] - Botao Bio, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 100% of its revenue derived from POCT products [1] Group 2 - According to data, the Fuguo Fund has a significant holding in Botao Bio, with the Fuguo Active Growth One-Year Regular Open Mixed Fund (009693) holding 613,800 shares, accounting for 4.27% of the fund's net value, making it the ninth-largest holding [2] - The Fuguo Active Growth One-Year Regular Open Mixed Fund has achieved a return of 62.46% this year, ranking 510 out of 8148 in its category, and has a total asset size of 578 million CNY [2] Group 3 - The fund managers of the Fuguo Active Growth One-Year Regular Open Mixed Fund are Yang Dong and Meng Hao, with Yang having a tenure of 10 years and 85 days, and Meng having a tenure of 3 years and 287 days [3] - Yang's fund has achieved a best return of 307.4% during his tenure, while Meng's fund has a best return of 35.76% [3]

Group 1 - The core viewpoint of the news is that Botao Bio has seen a stock price increase of 5.46%, reaching 46.20 CNY per share, with a total market capitalization of 6.899 billion CNY [1] - Botao Bio, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 100% of its revenue derived from POCT products [1] Group 2 - According to data, the Fuqua Fund holds a significant position in Botao Bio, with 613,800 shares representing 4.27% of the fund's net value, making it the ninth-largest holding [2] - The Fuqua Fund has achieved a year-to-date return of 64.11%, ranking 525 out of 8,155 in its category, and a one-year return of 63.45%, ranking 484 out of 8,031 [2] Group 3 - The fund managers of Fuqua Fund are Yang Dong and Meng Hao, with Yang having a tenure of 10 years and 76 days, and Meng having a tenure of 3 years and 278 days [3] - Yang's fund has a total asset size of 9.809 billion CNY, with the best return during his tenure being 329.8% and the worst being -38.34% [3] - Meng's fund has a total asset size of 4.565 billion CNY, with the best return during his tenure being 40.12% and the worst being -2.59% [3]

Group 1 - The core viewpoint of the news is that Botao Bio has seen a stock price increase of 5.01%, reaching 42.14 CNY per share, with a total market capitalization of 6.293 billion CNY [1] - Botao Bio, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 100% of its revenue derived from POCT products [1] - The trading volume for Botao Bio was 30.6043 million CNY, with a turnover rate of 0.49% [1] Group 2 - According to data, Guangfa Fund's Guangfa Value Core Mixed A Fund (010377) increased its holdings in Botao Bio by 1.5021 million shares in the second quarter, now holding 4.236 million shares, which is 2.84% of the circulating shares [2] - The fund has achieved a year-to-date return of 55.31%, ranking 428 out of 8162 in its category, and a one-year return of 62.05%, ranking 296 out of 8024 [2] - The fund manager, Wu Yuanyi, has a tenure of 5 years and 23 days, with the fund's total asset size at 20.478 billion CNY [2] Group 3 - The Guangfa Value Core Mixed A Fund (010377) holds Botao Bio as its eighth-largest position, with 4.236 million shares representing 2.75% of the fund's net value [3] - The estimated floating profit from this position is approximately 8.5144 million CNY [3]

Core Viewpoint - 博拓生物's stock performance shows a slight decline, with significant financing activity indicating high investor interest despite recent revenue and profit decreases [1][2]. Financing Summary - On September 15, 博拓生物 experienced a financing buy-in of 19.43 million yuan, with a net buy of 4.59 million yuan after 14.84 million yuan in repayments [1]. - The total financing balance reached 200 million yuan, accounting for 3.15% of the circulating market value, which is above the 90th percentile of the past year [1]. - No short selling activity was recorded on September 15, with a short balance of 0 yuan, also indicating a high position relative to historical data [1]. Company Performance Summary - As of June 30, 博拓生物 reported a revenue of 203 million yuan for the first half of 2025, reflecting a year-on-year decrease of 23.91% [1]. - The net profit attributable to shareholders was 12.40 million yuan, down 82.82% compared to the previous year [1]. - The number of shareholders decreased by 10.13% to 5,583, while the average circulating shares per person increased by 55.77% to 26,747 shares [1]. Dividend Summary - 博拓生物 has distributed a total of 798 million yuan in dividends since its A-share listing, with 478 million yuan paid out over the last three years [2]. Institutional Holdings Summary - As of June 30, 2025, the sixth largest circulating shareholder is 广发价值核心混合A, holding 4.236 million shares, an increase of 1.5021 million shares from the previous period [2].

Group 1 - The core point of the news is that 博拓生物's stock price has decreased by 5.01%, currently trading at 39.05 CNY per share, with a total market capitalization of 58.31 billion CNY [1] - 博拓生物, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 92.91% of its revenue coming from diagnostic reagent products [1] - The trading volume for 博拓生物 reached 2.27 billion CNY, with a turnover rate of 3.76% [1] Group 2 - From the perspective of major shareholders, 广发价值核心混合A (010377) holds 2.56% of 博拓生物's circulating shares, with a current floating loss of approximately 563.17 million CNY [2] - The fund has achieved a return of 68.54% year-to-date and 114.67% over the past year, ranking 147 out of 8194 and 129 out of 7963 respectively [2] - The fund manager, 吴远怡, has been in charge for 4 years and 333 days, with a total asset scale of 204.78 billion CNY [3] Group 3 - In the second quarter, 广发价值核心混合A (010377) held 423.6 million shares of 博拓生物, representing 2.75% of the fund's net value, making it the eighth largest holding [4] - The current floating loss for the fund regarding 博拓生物 is estimated at 872.62 million CNY [4]

Group 1 - On August 25, Botao Bio's stock increased by 0.15% with a trading volume of 201 million yuan [1] - The financing data shows that on the same day, Botao Bio had a financing purchase amount of 23.34 million yuan and a financing repayment of 26.15 million yuan, resulting in a net financing buy of -2.81 million yuan [1] - As of August 25, the total balance of margin trading for Botao Bio was 190 million yuan, which accounts for 3.11% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of March 31, the number of shareholders for Botao Bio was 6,212, a decrease of 2.11% from the previous period [2] - For the first quarter of 2025, Botao Bio reported an operating income of 87.89 million yuan, a year-on-year decrease of 35.20%, and a net profit attributable to shareholders of 8.73 million yuan, down 77.97% year-on-year [2] - Since its A-share listing, Botao Bio has distributed a total of 798 million yuan in dividends, with 478 million yuan distributed over the past three years [2]